Anti‐FIRΔexon2 autoantibody as a novel indicator for better overall survival in gastric cancer

There is no clinically available biomarker for efficiently indicating the overall survival or therapy response of gastric cancer (GC). The autoantibodies (Abs) in the sera of anti‐far‐upstream element‐binding protein‐interacting repressor‐lacking exon2 (FIRΔexon2), anti‐sorting nexin 15, and anti‐sp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Sci
Hauptverfasser: Kobayashi, Sohei, Hiwasa, Takaki, Ishige, Takayuki, Kano, Masayuki, Hoshino, Tyuji, Rahmutulla, Bahityar, Seimiya, Masanori, Shimada, Hideaki, Nomura, Fumio, Matsubara, Hisahiro, Matsushita, Kazuyuki
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2021
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7894018/
https://ncbi.nlm.nih.gov/pubmed/33306856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14767
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge